
    
      All consecutive patients with cirrhosis hospitalized with an infection or who developed an
      infection during hospitalization for an acute decompensation of the disease in four
      university hospitals.

      Criteria for inclusion were: 1/ cirrhosis as diagnosed by liver biopsy or a combination of
      clinical, biochemical, ultrasonographic, and/or endoscopic findings; 2/ age between 18 and 80
      years; 3/ presence of sepsis, as defined by infection and signs of Systemic Inflammatory
      Response Syndrome; and 4/ occurrence of type-1 HRS during the infection, as defined by
      standard diagnostic criteria. Exclusion criteria were: 1/ hepatocellular carcinoma outside
      the Milan criteria; 2/ any severe extrahepatic condition, including cardiovascular,
      neurological, and organic kidney diseases; 3/ septic or hypovolemic shock; 4/ terminal
      condition (death expected in less than 48 hours); and 5/ lack of informed consent.

      Aim: A proof of concept study to evaluate whether treatment with terlipressin and albumin in
      the course of an infection associated with type-1 HRS is effective and safe.
    
  